Roivant Sciences Ltd. (ROIV) shares climbed 13.95 percent to $32.15, up $3.94 on Wednesday, after the biopharmaceutical company reported a return to profitability in the fourth quarter of fiscal 2026, driven by a large litigation settlement gain.
The stock is currently trading at $32.15, compared with a previous close of $28.21 on the Nasdaq. It opened at $29.60 and traded between $29.35 and $32.25 during the session, with volume reaching 4.50 million shares, slightly below the average daily volume of 5.52 million shares.
Revenue declined to $2.5 million in the quarter ended March 31, 2026, from $7.6 million in the same period last year. Net income totaled $303.0 million, or $0.28 per share, compared with a net loss of $206.5 million, or $0.29 per share, a year earlier.
Roivant shares have traded between $10.59 and $32.25 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.